Back to top

Image: Bigstock

AngioDynamics Divests NAMIC Portfolio to Medline Industries

Read MoreHide Full Article

AngioDynamics, Inc. (ANGO - Free Report) ) recently completed the sale of its NAMIC fluid management portfolio to Medline Industries for $167.5 million. Proceeds from the transaction have been used to clear all of the company’s outstanding debt.

Additionally, the transaction is expected to accelerate investments in key therapeutic medical technologies like AngioVac, BioFlo and the NanoKnife System to address the unmet needs of patients. This fortifies the company’s foothold in the oncology devices market.

For investors’ notice, the divested fluid management portfolio consists of products like NAMIC Contrast Lines, NAMIC Closed Fluid Systems among others. In fact, in the last reported quarter, the unit witnessed strong year-over-year growth.

A Peek Inside AngioDynamics’ Product Portfolio

AngioDynamics’ product range includes vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products, and venous products. Notably, the Oncology unit includes Microwave Ablation, Radiofrequency Ablation, NanoKnife, BioSentry Tract Sealant System, Alatus, StarBurst XL and Semi-Flex RFA devices, UniBlate RFA Electrode and many more.

In recent times, the company received IDE approval from the FDA for the use of NanoKnife technology in the treatment of stage III pancreatic cancer.

Market Prospects

Per GBI Research, the global oncology device market revenues are expected to reach $241 billion by 2026 at a CAGR of 10.66%. Hence, AngioDynamics’ focus on oncology devices at this moment is well-timed.

However, the company competes with other bigwigs in the oncology devices space like Varian Medical (VAR - Free Report) , Accuray Incorporated (ARAY - Free Report) and Myriad Genetics (MYGN - Free Report) . Varian Medical’s Halcyon and HyperArc platforms deserve a special mention here. Meanwhile, Accuray’s CyberKnife currently enjoys robust demand while Myriad’s GeneSight is expected to witness solid growth in the times ahead.

Wall Street’s Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>